Search

Your search keyword '"Sowalsky, Adam G."' showing total 417 results

Search Constraints

Start Over You searched for: Author "Sowalsky, Adam G." Remove constraint Author: "Sowalsky, Adam G."
417 results on '"Sowalsky, Adam G."'

Search Results

55. Supplementary Data from Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications

57. Supplementary Figure S3. from Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors

58. Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer

59. Supplementary Figures 1-8 from ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer

60. Supplementary Table S1. from Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors

61. Data from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer

62. Data from Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations

63. Supplementary Data from A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes

65. Supplementary Materials from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening

66. Supplementary Data from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer

67. Supplementary Data from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer

68. Supplemental Information from Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations

69. Supplemental Figures S1-S5 from Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations

70. Supplementary Tables S1,S2,S3,S4,S9 from Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations

71. Supplementary Figures from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening

73. Supplementary Tables from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening

75. Supplementary Figure from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer

76. Supplementary Table 4 from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening

84. AR Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

85. SOX9 drives WNT pathway activation in prostate cancer

86. Defining cellular population dynamics at single-cell resolution during prostate cancer progression

87. Author response: Defining cellular population dynamics at single-cell resolution during prostate cancer progression

90. Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer

91. Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood

92. Defining biology and recurrence risk in prostate cancers treated by neoadjuvant chemohormonal therapy.

95. Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer

96. Prediction of cancer treatment response from histopathology images through imputed transcriptomics

97. A genotoxic antibody drug conjugate targeting CD276/B7H3 demonstrates efficacy across multiple biomarker defined classes of treatment refractory metastatic prostate cancer

98. A cancer stem cell population underlies a multi-lineage phenotype and drug resistance in prostate cancer

99. Defining cellular population dynamics at single cell resolution during prostate cancer progression

100. Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer

Catalog

Books, media, physical & digital resources